AdvanCell has raised $315M in a Series D round to accelerate development of its AI-powered targeted radiotherapy platform, making it one of the larger biotech private financings in July.
The company develops targeted alpha therapy for solid tumors, using AI to optimize isotope selection and patient targeting. Targeted alpha therapies deliver potent radiation directly to cancer cells while sparing healthy tissue, but matching the right isotope to the right tumor type has historically been a complex trial-and-error process.
AdvanCell’s AI models analyze tumor biology, biomarker expression and isotope decay characteristics to predict which patients are most likely to benefit from specific alpha-emitting combinations. The company says this computational approach cuts development timelines and improves the probability of clinical success.
The $315M Series D — a round size that stands out in the current biotech funding environment — reflects growing investor confidence in radiopharmaceuticals as a therapeutic modality. The sector has attracted significant interest as drug developers seek alternatives to traditional chemotherapy and immunotherapy approaches.
Proceeds will fund ongoing clinical trials, expand manufacturing capacity for radioisotopes and scale the AI platform that underpins the company’s patient selection strategy. The round was oversubscribed, signaling strong demand for AI-enabled precision oncology approaches.
